FAQ

The purpose of this research is to test the efficacy of a treatment, Azeliragon for severe COVID-19 infections in hopes of reducing need for hospitalizations, mechanical ventilations, acute kidney injury, and deaths. 

1. To participate in the study, participants must be admitted to University of Michigan Hospital with a primary diagnosis of COVID-19. 

2. Participants must be 18 years of age or older.

Contact Tonimarie Catalan if you think you may be eligible and are interested in participating.

Azeliragon is an oral pill that works by inhibiting proteins in your body that cause inflammation and other life-threatening outcomes when infected with COVID-19. 

Azeliragon is produced by Cantex Pharmaceuticals. 

Participation involves taking Azeliragon for up to 10 days, or only for as long as you are hospitalized, if less than 10 days. You will take the pills twice daily for 5 days then once daily for up to 10 days. 

Patients will be observed for adverse events during their hospitalization and then we will follow up with you at day 14, 30 and 60 days after your last dose of study treatment. 

Your treatment can take up to 10 days, depending on how long you're hospitalized. Participants will be followed for about two months after their last dose of the study drug, Azeliragon. 

To be in this study, participants must be in admitted to University of Michigan Hospital.  

Follow-up appointments can be completed over the phone.

Participants can be compensated up to $250:  $50 upon completion of treatments, and $50 for completing each follow-up appointment. 

Our study is being conducted while you are hospitalized for COVID-19 at the University of Michigan Hospital located at 1500 E Medical Center Dr. Ann Arbor, MI  48109